Maximising uptake and utilization of molecular
diagnostics: lessons from implementation
evaluation of tuberculosis diagnostics
Nyanda Elias Ntinginya
National Institute of Medical Research-Mbeya Medical Research Centre
Fred Orina
Kenya Medical Research Institute
Ivan Mwebaza
Makerere University
Alphonce Liyoyo
Institute of Clinical Research Institute
Barbara Miheso
Kenya Medical Research Institute
Augustus Aturinde
Lund University: Lunds Universitet and Kyambogo University
Fred Njeleka
National Institute of Medical Research-Mbeya Medical Research Centre
Fred Njeleka
National Institute of Medical Research-Mbeya Medical Research Centre
Elizabeth F Msoka
Kilimanjaro Clinical Research Institute
Helen Meme
Kenya Medical Research Institute
Erica Sanga
National Institute for Medical Research-Mbeya and Mwanza Research Centres
Erica Sanga
National Institute for Medical Research-Mbeya and Mwanza Research Centres
Davis Kuchaka
Kilimanjaro Clinical Research Institute
Simeon Mwanyonga
National Institute for Medical Research - Mbeya Medical Research Centre
Willyhelmina Olomi
National Institute for Medical Research - Mbeya Medical Research Centre
Linda Minja
Page 1/20
Kilimanjaro Clinical Research Institute
Linda Minja
Kilimanjaro Clinical Research Institute
Moses Joloba
Makerere University
Blandina Theophil Mmbaga
Kilimanjaro Clinical Research Institute
Evans Amukoye
Kenya Medical Research Institute
Stephen H Gillespie
University of St Andrews
Wilber Sabiiti ( ws31@st-andrews.ac.uk )
The University of St Andrews https://orcid.org/0000-0002-4742-2791
Research
Keywords: Implementation, Molecular diagnostics, Tuberculosis, Maximising uptake and utilization,
policy and practice.
DOI: https://doi.org/10.21203/rs.3.rs-106037/v1
License: This work is licensed under a Creative Commons Attribution 4.0 International License.
Read Full License
Page 2/20
Abstract
Background: Tuberculosis (TB), a treatable disease claims over a million lives every year. Accurate rapid
diagnosis is crucial for early treatment initiation and prevention of severe disease. Despite over 10 years
approval of molecular diagnostics for routine use, an estimated 3 million TB cases go undetected per
year. We investigated the barriers and opportunities to maximise uptake and utilization of molecular
diagnostics in routine healthcare settings.
Methods: We deployed surveys, healthcare facility audits, focus group discussions, in-depth interviews,
and policymaker dialogues to unravel factors affecting the uptake and utilization of TB molecular
diagnostics in three East African countries. The benchmark was the World Health Organization approved
Xpert MTB/RIF and Line Probe Assay (LPA) implemetation at district and regional hospital level
respectively.
Results: 190 district and county health o cers participated in the survey. The survey ndings were
corroborated by 145 healthcare facility (HCF) audits and 11 policymaker engagement workshops. At 66%
coverage, Xpert MTB/RIF fell behind microscopy and clinical diagnosis by 33% and 1% respectively
across 190 districts/counties. Strati ed by HCF type, Xpert MTB/RIF implementation was 56%, 96% and
95% at district-, regional- and national referral- hospital level. LPA coverage was 4%, 3% below culture
across the three countries. Out of 111 HCFs with Xpert MTB/RIF, 37 (33%) utilized it to full capacity,
performing ≥8 tests per day of which 51% of these were level ve (zonal consultant and national referral)
HCFs. Likewise, 75% of LPA test performance was at level ve HCFs. Underutilization of Xpert MTB/RIF
and LPA was mainly attributed to inadequate- human resource, 22% and utilities, 26% respectively.
Absence of the diagnostic services was attributed to under nancing. Lack of awareness was second to
under nancing as reason underlying absence of LPA service. Creation of a health tax and decentralising
collection and management of this tax to district/county level was proposed by policymakers as means
to boost domestic nancing for uptake of health technologies.
Conclusion Our ndings show higher uptake and utilization of molecular and other diagnostics at tertiarythan primary-secondary- level HCFs. Innovative implementation models to ensure quality access at lower
level HCFs are urgently needed.
Contributions To Literature
This study shows implementation of molecular diagnostics is higher at tertiary healthcare level
contrary to World Health Organization recommendation to have them at lower healthcare level where
they could be accessed by the majority.
It demonstrates that utilization of molecular- and culture- based diagnostics that require advanced
laboratory facilities increases the higher you go in the health system hierarchy, which implies low
access by people living farther a eld.
Page 3/20
The study shows that it is not only the unavailability of nances that drives poor implementation but
also mechanisms by which the nances are invested and priorities set.
Introduction
The COVID-19 pandemic led to world-wide shutdown and seen unprecedented uptake and utilization of
molecular diagnostics with over 500 million tests conducted in a period of 9 months (statista.com Oct
9th 2020). The rapidly evolving COVID-19 is responsible 36.99 million cases and 1.1 million deaths (WHO
COVID-19 Dashboard 11th Oct 2020)(1). The health systems have been shaken but most importantly the
pandemic has raised public consciousness of the value of diagnostics and interdisciplinary approaches
in the control of diseases. In contrast, tuberculosis (TB) has been a pandemic for time immemorial and a
global public health emergency for over 20 years(2, 3). A quarter (1.7 billion) of the world population have
TB infection and in 2018, 10 million developed active disease resulting in 1.5 million deaths(4–6). Of the
10 million noti ed cases, 55% were bacteriologically con rmed and a small proportion of these were
tested using rapid molecular tests(5). The rate of TB testing does not match incidence of TB disease and,
consequently, an estimated 3 million cases go undetected every year(7).
WHO approved routine use of TB molecular tests more than 10 years ago, starting with the Line Probe
Assay (LPA) in 2008 and Xpert MTB/RIF in 2010(8, 9). The latter detects both TB and resistance to
rifampicin in 2 hours and is the widely used molecular test for TB. By 2016, only 16 million Xpert
MTB/RIF tests had been performed, translating into 3.2 million tests per year(10). Whilst there is been
steady progress in the uptake and use of Xpert MTB/RIF, the impact of using the same GeneXpert
platform for testing HIV viral load and more recently COVID-19 on TB diagnosis is yet to be unravelled(11,
12). There is sharp contrast in the rate of uptake of COVID-19 molecular tests compared to TB and could
a leaf be borrowed from either disease on how to accelerate and maximise translation of health research
innovations into policy and practice.
The impact of effective diagnostic testing is not only the ability to detect disease but also contribution to
favourable clinical outcomes for patients. This is more likely to be achieved in a health system landscape
that employs holistic approach to patient care as enshrined in the “WHO End TB strategy”: integrated
patient-centred care and prevention to foster early diagnosis, universal drug-susceptibility testing,
systematic screening of contacts and high-risk group, treatment of all people. Good governance and
leadership to ensure equal access to healthcare, safe medicines and social protection to minimise impact
of economic status on quality of care received. Last but not least, intensifying research and innovation to
ensure discovery, development, optimisation and rapid uptake of new tools, interventions and strategies
coupled with monitoring and evaluation to ascertain impact(13–15).
Low- and Middle- Income Countries (LMICs) account for over 50% of the global TB burden(5). The
scarcity of resources complicates the development of strong health systems and more so the COVID-19
effect which is estimated to have reduced TB care delivery by 20% is taken into account(12). Models to
ensure access of service by those that need them the most have been developed(16–18). For instance,
Page 4/20
Kenya recently used Patient Pathway Analysis (PPA) model to assess the delivery of TB diagnostic and
treatment and found more than 50% of the low-level healthcare facilities (HCFs) where majority people
seek care did not have diagnostic services(19). Confronted by this nding, Kenya committed to
redesigning the provision of TB services to ensure they are in places where they are most needed rather
than where it is operationally convenient, such as tertiary level healthcare facilities (HCFs) in urban
settings. Kenya adopted this approach around the same time as our study, it will be interesting to assess
the impact made on uptake and utilization of molecular diagnostics for TB in the country.
Using the implementation of TB diagnostics as a model, we sought to understand the ways to maximise
uptake and utilization of diagnostic technologies that have regulatory approval and are supported by
WHO and other expert opinion within the health systems. Our ndings show higher rate of uptake and
utilization of TB diagnostics at tertiary level HCFs. In contrast to the WHO endorsement, LPA is mainly
implemented at zonal – national level instead of regional HCF while Xpert MTB/RIF was more utilised at
regional, zonal – national level HCFs instead of the recommended district level hospitals. These data
point to hub-centralised model of implementation in order to maximise both uptake and utilization of the
diagnostics platforms. Resolving the health system, socioeconomic and cultural bottlenecks is pivotal for
the effective implementation of either the PPA or centralised model of diagnostic services.
Methods
This was a mixed methods study employing both quantitative and qualitative approaches including
surveys of district/county health o cers, healthcare facility audits, in-depth one-on-one interviews, focus
group discussions and dialogues with policymakers. The study was conducted between Sept 2016 to Dec
2017 in Uganda, Kenya and Tanzania. At the time of the study, only Kenya was de ned as a middle
income country, and it has now been joined by Tanzania in this classi cation(20).
Consortium
The study was conducted under the TWENDE consortium and comprised 7 institutions: Makerere
University and CPAR Uganda Ltd Uganda, Kenya Medical Research Institute (KEMRI) Kenya, Kilimanjaro
Clinical Research Institute (KCRI) and National Institute of Medical Research – Mbeya Medical Research
Centre (NIMR-MMRC) Tanzania while the East African Community was represented by the East African
Health Research Commission (EAHRC) and University of St Andrews, UK. TWENDE, which is Swahili word
means “let’s go!” is abbreviated from Tuberculosis: Working to Empower the Nations’ Diagnostic Effort.
Geography and participants
Areas of coverage were selected based on the TB diagnostics, Line Probe Assay (LPA) and Xpert
MTB/RIF (GeneXpert) approved areas of implementation. According to the World Health Organisation,
LPA and Xpert MTB/RIF are recommended for implementation at regional and district level hospitals
respectively. In Uganda, regions were based on areas represented by a regional hospital whilst districts
were taken as they are currently structured as administration units. In Tanzania, regions and districts are
clearly demarcated administrative units and so were covered as such. For Kenya, regional units were
Page 5/20
counties whilst the sub-counties were equivalent to districts in Uganda and Tanzania. Study districts,
regions or counties were purposively selected to be representative of all geographical regions of the
country.
Participants were healthcare administrators such as regional/county and district health (medical)
o cers, HCF managers and healthcare professionals of participating HCFs. Apart from managers and
practitioners, patients, TB survivors, Community health Volunteers, opinions leaders among the HCF
users, local council leaders, and national policy makers in ministry of Health and parliament were
engaged. Participants were selected based on their role either as healthcare leader/manager or
practitioner and/or by their status as TB patients, caregivers or survivors. The managers and practitioners
represented opinion from health system service delivery perspective whilst the patients, caregivers and
survivors shared their lived experiences in accessing diagnosis and treatment as well as living with TB in
a community.
Survey
An online survey was constructed using the University of St Andrews licenced Qualtrics survey tool
(https://standrews.eu.qualtrics.com). The tool was commissioned by the University of St Andrews
teaching and research ethics and complies with the European Union General Data Protection regulation
(GDPR) EU2016/679 and the local country Ethics committees. The purpose of the survey was to obtain
an overview of the challenges and opportunities confronting tuberculosis diagnostics and treatment
services from the perspective of regional/county and district/sub-county health or medical o cers (see
Additional le 1: Survey Questionnaire). It sought to know what facility and/or service is available and if
not available, what could be the underlying reasons. The survey was made compatible with all computer
systems, Windows and macOS, and both Android and Apple smart phones. The opening page of the
questionnaire had participant information and solicitation for consent to participate in the study.
Healthcare facility audits
The rationale of the audit was to verify the responses given by survey participants and gain more insight
into the implementation of TB diagnostics on ground. The audit tool was developed and teams of
researchers in each country were trained to administer the tool at selected healthcare facilities. The
respondents at the HCFs were the healthcare and laboratory managers at regional/county and
district/sub-county hospitals. The audit ascertained whether the facilities and services reported by the
survey participants were indeed available and being utilized. In addition to interviews with healthcare
practitioners, the auditors inspected the facilities to verify answers given. See Additional le 2: the Audit
tool.
Policy dialogues
Workshops were organised targeting policy makers and implementers to discuss views from the general
community and construct actionable policy briefs for the national policies to implement. Participants in
these were workshops were parliamentarians, technocrats from Ministries of Health, leaders from
regional/county administrative units, and representatives of other disease control agencies.
Page 6/20
“Chatham House Rules” were used during the FGDs and policy dialogues to promote open expression of
views and opinions without fear of being vili ed. The Chatham rule states: “When a meeting, or part
thereof, is held under the Chatham House Rule, participants are free to use the information received, but
neither the identity nor the a liation of the speaker(s), nor that of any other participant, may be revealed”.
Data Analysis
Quantitative data was analysed using Microsoft Excel 2016 and GraphPad Prism v.6. Percentage
diagnostic coverage and utilization was calculated per type of HCF and all HCFs combined. ANOVA
multiple comparisons test was used to assess the performance difference between HCFs. Signi cance
was considered at p < 0.05 and 95% con dence interval (CI).
Results
Participants and study area
A total of 217 survey responses received from district or county healthcare o cers across the three
countries. After removal of duplicate/multiple responses per district or county, 190 entries representing 27
(14%), 66 (35%) and 97 (51%) from Kenyan counties, Tanzanian and Ugandan districts respectively were
considered for analysis. The Kenyan county was considered equivalent of Ugandan or Tanzanian region.
The 27 Kenyan counties varied in size, median (range) 5 (2–17) sub-counties (districts), together
constituting an area of 159 sub-counties and 57% of Kenyan counties. All the 14 Ugandan and 26
Tanzania mainland regions were represented in the survey. Time spent in the post by respondents ranged
from less than one year to 16 years: 14 (7%) less than one year, 35 (16%) one to two years, 53 (24%) three
to four years, 41 (19%) ve to six years, 29 (13%) seven to eight years, 16 (7%) nine to ten years and 29
(13%) over10 years.
The on-site audits healthcare facilities (HCFs) recapitulated the survey results. A total of 145 HCFs were
audited, 48 (33%) each for Kenya and Uganda and 49 (34%) Tanzania. This represents 42% (112), 29%
(169) and 44% (47) of the districts and counties in Uganda, Tanzania and Kenya respectively at the time
of audit. In all the countries, government was the main healthcare provider, owning over 80% of the
healthcare facilities. Level 5 hospitals (national, consultant level, regional referral) were 42, level 4
(regional hospitals) 34, level 3 (district hospitals) 57, level 2 (health centre IV) 6 and level 1 (dispensary,
health centre 1–3) 6. The majority of the tuberculosis laboratories were able to deliver Biosafety level II
(BSL II), 86 followed by BSL I, 23 and BSL III, 6 and 4 general laboratories.
Coverage of diagnostics
At the time of the survey; smear microscopy was the most available diagnostic tool, 97% (185/190)
followed by clinical diagnosis, 67% (128/190) and Xpert MTB RIF, 66% (125/190) of the districts/counties
surveyed. Tuberculosis culture and Line Probe Assays (LPA) were the least available, 7% (13/190) and 4%
(8/190). Most of the districts, 89% (169) reported microscopy in combination with other diagnostics
leaving only 11% (21) which had only microscopy for diagnosis. At country level, Xpert MTB/RIF test
Page 7/20
coverage was 74% (72/97) and 39% (26/66) districts in Uganda and Tanzania respectively and 42%
(67/159) sub-counties in Kenya (Fig. 1).
The number of Xpert MTB/RIF test machines (GeneXpert) was not consistent with the number of subcounties (districts) per county in Kenya. Some counties had less than the number of the sub-counties and
vice versa (Fig. 2).
The coverage results were replicated in the on-site audit of 145 HCFs: smear microscopy availability 142
(98%), Xpert MTB/RIF 111 (76%), Culture 5 (4%) and LPA 4 (3%). Number of available of Xpert MTB/RIF
instruments increased with increasing level of HCF. Out of the 111 HCFs possessing Xpert MTB/RIF, 1
(0.9%), 5 (5%), 32 (29%), 33 (30%) and 40 (36%) were level 1, 2, 3, 4 and 5 HCFs respectively. Availability
within the HCF type, level 4 and 5 had the highest, 97% and 95% coverage of Xpert MTB/RIF instruments
followed by level 2, 83%, level 3 (56%) and level 1, 17% (Fig. 3).
Out the 4 HCFs in possession of LPA, three were L5 (1 national-, 1 zonal- referral and 1 consultant
hospital), and only one was L4 (regional). All the ve HCFs with culture were L5 (2 national referral, 2
consultant and 1 zonal referral hospitals).
Utilization of diagnostics
Smear microscopy
Taken together, number of smears performed per month by HCFs with microscopy services (142) were
median (range) 56 (0·8-460). The number of smears performed increased with the HCF level, 26 (17–75),
18 (1·3–60), 46 (0·8-460), 48 (1·3-400) and 89 (5-311) at HCF level 1, 2, 3, 4 and 5 respectively. Only HCF
level 5 performed above median number of smears per month. Of the 142 HCFs that performed
microscopy, 96% (137) used it for diagnosis and treatment follow-up. The most frequent use of smear
microscopy was treatment follow-up, 50% (68) followed by combination of primary diagnosis and
treatment follow-up, 40% (55). The proportion of using microscopy as a primary diagnostic tool was high,
33% in level one (L1) HCFs versus 10% in L5 HCFs, and 67% versus 26% for using microscopy for both
primary diagnosis and treatment follow-up (Table 1)
Page 8/20
Table 1
Utilization of smear microscopy in audited HCFs. There is high utilization of microscopy as a primary
diagnostic tool in lower level HCFs
Total
L1 (N =
6)
L2 (N =
6)
L3 (N =
57)
L4 (N =
34)
L5 (N =
42)
Primary diagnosis
12
2 (33%)
0%
6 (11%)
0%
4 (10%)
Primary diagnosis of HIV negative
cases
2
0 (0%)
0%
2 (4%)
0%
4 (10%)
Primary diagnosis and Follow-Up
55
3 (67%)
3 (50%)
30
(53%)
7 (21%)
11
(26%)
Follow-up only
68
0 (0%)
3 (50%)
17
(30%)
24
(71%)
24
(57%)
Xpert MTB/RIF
Like coverage, utilization of Xpert MTB/RIF increased with level of HCF, median (IQR) 0 (0–4), 90 (33–
390), 120 (55–170), 200 (110–240), 228 (110–320) tests per month at level 1, 2, 3, 4 and 5 HCF
respectively, linear regression p = 0·002. The ordinary one-way ANOVA multiple comparisons test showed
signi cant difference of tests performed at different HCFs, F = 5·4, p = 0·0005. However, the difference
was driven by tests at level 4 and 5 which were signi cantly higher than level 1 and both level 1 and 3
HCFs respectively. Out of the 111 sites with Xpert MTB/RIF test instruments, only 37 (33%) utilized the
instruments to full capacity, performing at least 8 tests per day or 240 tests per month. Of the HCFs using
Xpert MTB/RIF to full capacity, 8% (3), 14% (5), 27% (10) and 51% (19) of these HCFs were level 2, 3, 4
and 5 respectively. None of the level 1 HCFs performed Xpert MTB/RIF to capacity (Fig. 4A and B).
All Xpert MTB/RIF test machines except 2 (1·8%) were operated in designated laboratory space and not at
point-of-care (consultation room) or ward. Most HCFs prescribed Xpert MTB/RIF test to all presumptive
TB cases, 86% (95/111). Where Xpert MTB/RIF was not prescribed to all these groups of cases were
prioritised, “health workers, prisoners, children (0–14 years), diabetic mothers, HIV positive clients who are
coughing and on retreatment,, contacts of drug resistant TB patients, retreatment cases, treatment
absconders, relapse cases, re- treatment cases, refugees, and expecting mothers”. It is important to note
that by the end of 2019, Kenya, Tanzania and Uganda had updated their national TB control guidelines
recommending Xpert MTB/RIF test to all presumptive cases hence more HCFs are currently having the
Xpert MTB/RIF machines. Xpert MTB/RIF machine operational condition and reagent procurement were
assessed and showed 87% (96/111) of the HCFs had their machines calibrated, 89% (99/111) had stable
supply of cartridges and 76% (85/111) received the cartridges on time. The magnitude of effect by each
factor varied from HCF-to-HCF with a trend to better service at high HCF level (Fig. 5A-F).
Line Probe Assay (LPA)
Page 9/20
Utilization of the LPA was quite irregular. Out of the 4 HCFs that had an established LPA service, one
performed it on request (64 tests per month), the 2nd was twice a month (24 tests per month) and the 3rd
performed only the day they were trained and since then never performed it again. When asked what the
limiting factor was for not performing LPA again, they said, “can’t tell, a team came here trained us on
LPA and left. since then we have never done anything, we actually don’t remember what we learnt”
Laboratory manager at a Regional Hospital. The fourth HCF gave no answer on how they utilized their
LPA service. Of the 4 HCFs that had LPA, 3 (75%) were level 5 and 1 (25%) was level 4.
Underlying limitations for underutilization or absence of Xpert MTB/RIF and LPA services
Some HCFs that had Xpert MTB/RIF attributed underutilization of the service to inadequate human
resource 22% (24/111), procurement di culties, 12% (13/111), poor electricity- and water- supply, 12%
(24/111) and 6% (7/111) respectively. The lack of Xpert MTB/RIF and LPA services was mainly attributed
to insu cient nance at both district/county level (91% and 55%), and at the HCF level (56% and 21%)
respectively. Lack of awareness was a second limiting factor to nancing revealing 33% and 49% of the
district/county health o cers and healthcare practitioners were unware of the LPA as a diagnostic test
for TB. Inadequate human resource (24%), lack of water (26%) and electricity (26%) were also considered
substantial limitation of implementation of Xpert MTB/RIF by practitioners at their HCFs (Table 2). 6–9%
reported procurement di culties for the two diagnostics, which included reagent stockouts and delayed
payment of requisitions by the healthcare management. “Failed procurement is not necessarily due to
distant (overseas) sources of laboratory supplies, in most cases it is due to bureaucracy associated with
releasing payments, sometimes taking up to 9 months to honour requisition or pay an invoice yet we
have a stock of LPA kits here in Nairobi”, Kenyan Hain Life sciences o cer.
Page 10/20
Table 2
The factors underlying lack of Xpert MTB/RIF and LPA services at district/county- and healthcare facilitylevel. The respondents were district (Uganda & Tanzania) and/or county (Kenya) health o cers and
healthcare practitioners.
District/County level
Limitation underlying absence of the
diagnostic test
Xpert MTB/RIF (N
= 76)
Healthcare facility
level
LPA
(N =
201)
Xpert
MTB/RIF
LPA
(N = 34)
(N =
138)
Under nancing
91%
55%
56%
21%
Procurement di culties
9%
7%
6%
8%
Inadequate human resource
1%
3%
24%
0%
No water
1%
0%
26%
0%
No electricity
0%
1%
26%
0%
Biosafety issues
3%
1%
0%
0%
Only available at regional hospital
0%
3%
0%
3%
Not aware of the test
0%
33%
0%
49%
Inadequate space and test complexity were also identi ed as reasons for underutilization of LPA. In
principle conducting LPA requires three rooms (pre-PCR, PCR and post-PCR) to perform, “Very few
healthcare facilities in the country have such space and person time to perform LPA”, Tanzanian senior
laboratory scientist.
Culture
Like LPA, culture was a less utilised diagnostic, 49·6% (72/145) of the facilities that we audited. The
median (range) of culture testing was 1 (0-347) test per month. Whilst no culture test was prescribed by
HCF level one, L2, L3, L4 and L5 prescribed 0.1 (0-0.2), 0.3 (0–36), 0.4 (0–13) and 10 (0-347) cultures per
month respectively. Utilization improved with HCF level, 0% (0/6), 33% (2/6), 40% (23/57), 65% (22/34)
and 60% (25/42) level 1, 2, 3, 4 and 5 HCFs referring samples for culture. Where culture was prescribed,
the percentage referral for drug sensitivity testing (DST) was 25% (18/72) overall and varied across HCF
levels, 17% (1/6), 9% (5/57), 6% (2/34) and 24% (10/42) at different HCF level 2–5 respectively. Time to
culture restult was on average 2 month for all HCF (Fig. 6A and B).
Monitoring response to anti-tuberculosis therapy
Most of the 145 audited HCFs, 79% (114) used microscopy as the only tool for monitoring treatment. This
included 83% (5/6), 50% (3/6), 82 (47/57), 88% (30/34) and 69% (29/42) level 1, 2, 3, 4 and 5 HCFs
respectively. Other treatment monitoring methods used alone were clinical assessment, 2% (3) and Xpert
Page 11/20
MTB/RIF 0.7% (1). One of each level 2, 3 and 5 HCF used clinical assessment only while one level 3 HCF
used Xpert MTB/RIF. Some HCFs used a combination of monitoring methods, 3% (4), 4% (5), 4% (5), 1.4%
(2) and 0.7% (1) for microscopy-clinical assessment, microscopy-Xpert MTB/RIF, Xpert MTB/RIF-culture
and microscopy-Xpert MTB/RIF-chest X-ray respectively. Combination of microscopy and culture was
available at two level 4- and three level 5- HCFs only. Microscopy-Xpert MTB/RIF was present at one level
1 and two of each level- 3 and 5 HCFs while microscopy-Xpert MTB-chest X-ray was available at one level
3 hospital.
Human resource capacity
We asked whether human resource capacity varied between HCF levels. All HCFs employed certi cate
and diploma level laboratory technicians and medically quali ed staff with highest proportion (100%) at
level 1 and 2 HCFs respectively. There were no Bachelor degree quali ed laboratory staff at level 1 HCFs.
The highest proportion of master’s degree holders, 38% and clerical staff, 75% was found at level 5 HCFs
(Table 3).
Table 3
Human resource capacity at different HCF levels. There is a trend to more highly quali ed staff working in
higher HCF levels.
Human resource proportional to number of that HCF
type
Human resource
capacity
N (median
(range)
L1
L2
L3
L4
L5
(6
HCFs)
(6
HCFs)
(57
HCFs)
(34
HCFs)
(42
HCFs)
Certi cate holders
2 (0–2)
100%
83%
96%
65%
81%
Diploma holders
4 (0–18)
83%
100%
97%
91%
93%
Bachelor’s degree
holders
2 (0–16)
0%
83%
57%
68%
93%
Master’s degree
holders
0 (0–6)
0%
17%
0%
15%
38%
Medically quali ed
5 (0–60)
100%
67%
83%
82%
74%
Clerical staff
1 (0–35)
17%
33%
63%
38%
57%
Diagnostic choice making
With a sub-set of healthcare practitioners (N = 22), we explored the qualities they would consider to
choose a diagnostic test for their practice. 95% and 82% of the practitioners preferred an expensive but
more accurate and harder to perform but shorter time-to-result diagnostic to a low cost – less accurate
and longer time-to-result test respectively (Table 4).
Page 12/20
Table 4
Qualities that inform choice of diagnostic test by practitioners. Accuracy and shorter time-to-result were
considered more import than cost and ease of performing a test.
Diagnostic characteristic
No. of participants who made the choice
%
Expensive but more accurate
21
95
Cheap but less accurate
1
5
Longer time-to-result (2 weeks) but easy to perform
4
18
Shorter time-to-result (4 h) but hard to perform
18
82
Policymakers’ engagement
Policy makers were engaged at the initiation-, during and after completion- of the study. Pre-study
engagement gave policymakers’ perspective on the important matters the study should focus on and the
channels through which ndings can be communicated to policy making organs. A total of 11
policymakers engagement workshops were held, three each in Kenya and Tanzania and ve in Uganda.
Dialogues ranged from ways to make research to policy making to sustainable uptake and utilization of
diagnostic technologies for better health outcomes. Policy makers were keen to be involved in research
right from inception to the end in order to increase translation of outputs into policy and practice.
Demonstrating research outcomes and impact at county (region) level before scale-up to national level
was particularly recommended as the best way to increase uptake of health research innovations.
Creating a national health tax and permitting county-regional governments to invest a percent of local
collected revenues was proposed as means of increasing domestic nancing and ensure sustainable
uptake and utilization of health technologies.
Discussion
Early diagnosis of tuberculosis is essential because it shortens time to appropriate treatment, prevents
severe morbidity and mortality(15, 21). We set out to understand the barriers that hinder uptake of health
research innovations and identify opportunities to maximise translation of these innovations into policy
and practice in Low- and Middle- Income (LMIC) setting. Using implementation of tuberculosis
diagnostics as a model, we found that barriers can be categorised into health system and socioeconomic
– cultural barriers. In this paper we focus on health system challenges and show that uptake and
utilization of molecular and microbiological (culture) diagnostics in LMIC setting is still below
expectation. Low uptake of diagnostics was mainly attributed to under nancing of healthcare followed
by lack of awareness by both district health o cers and practitioners at healthcare facilities.
Procurement di culties, inadequate human resource and utilities such as water and electricity were
highlighted as underlying sub-optimal utilization of molecular diagnostics hereby referred as Xpert
MTB/RIF and LPA.
Page 13/20
Information given by district/county health o cers through the online survey was corroborated by on-site
HCF audits and interview of practitioners demonstrating the real situation on ground. While the private
sector plays a major role in providing healthcare in the studied countries, government was found to be the
key stakeholder providing over 80% of tuberculosis diagnostic and treatment services. This further
emphasises the important position government occupies to identify and overcome underlying health
system limitations and to maximise the uptake of health technologies ensuring they reach where they are
needed most.
Despite its technical limitations, smear microscopy was widely implemented and utilized diagnostic for
tuberculosis at all levels of the healthcare system in Kenya, Tanzania and Uganda(22, 23). We believe
low- acquisition cost, space and energy requirements make the microscope more attractive for healthcare
facilities to implement(24). Furthermore, the microscope is a multipurpose platform often serving other
functions such as diagnosis of malaria, helminths and other bacterial infections in low income countries.
Technical limitations such as low sensitivity and speci city for diagnosing tuberculosis have less impact
on the choice of diagnostic methodology. Technical challenges notwithstanding, for example the low
sensitivity of smear microscopy revealed by the 2016 Kenya TB prevalence survey where smear
microscopy only detected 46% cases compared to 78% by Xpert MTB/RIF(25), a device that serves other
diagnostic needs at the HCF makes more economic sense when deciding technologies to purchase.
Therefore, investing in open rather than closed systems will go a long way in maximising uptake of new
health technologies into policy and practice.
The World Health Organisation (WHO) approved Xpert MTB/RIF for implementation up to district hospital
level9. Our results show that, out of the 57 level 3 (district/sub-county) hospitals, only 56% had the Xpert
MTB/RIF instruments and only 14% utilized the instruments to capacity i.e., performing 8 or more tests
per day. There was, instead, higher, close to 100% coverage at level 4 and 5 HCFs with corresponding high
full capacity utilization of 27% and 51% respectively. It is therefore not clear the model followed in
allocating the Xpert MTB/RIF instruments. For instance, in Kenya some counties had more than one Xpert
MTB/RIF instruments per sub-county while others had two instruments serving over 10 sub-counties. In
line with this observation Oliwa et al found variability in spatial distribution of diagnostic services in
Kenya suggesting a non-need driven allocation of diagnostic platforms(26).
Only 2 (1.4%) of the audited HCFs used the Xpert MTB/RIF at point-of-care (in consultation room). In
most cases Xpert MTB/RIF results were not available in the same day, which means the speed advantage
of Xpert MTB/RIF is not being realised. It is also not clear whether both doctor consultation and Xpert
MTB/RIF testing were going on in the same room. The higher the HCF was in the health system hierarchy
the higher the utilization of Xpert MTB/RIF instruments. Limitations such as procurement, inadequacy of
utilities and human resources were less frequent at higher level HCFs. In line with Poorani et al, our
ndings show that a hub system with an effective sample referral network may be more cost-effective
than placing Xpert MTB/RIF machine at every healthcare facility(27). With this approach, Xpert MTB/RIF
may no longer qualify as near point-of-care test but its utilization will be more cost-effective. It has been
suggested, however, that decentralisation of Xpert MTB/RIF can be cost-effective if the testing volumes
Page 14/20
are high in peripheral HCFs(28) and there is good ow of funds to ensure availability of consumables.
The high testing volume – decentralisation model contradicts the novel battery powered single module
point-of-care GeneXpert OMNI because it would require 16 h to test 8 samples thus increasing turnaround-time and cost more to implement in high TB burden settings(29, 30).
The Line probe Assay was the least implemented diagnostic test, yet it is the only approved rapid drug
sensitivity testing (DST) diagnostic for multi-drug resistant TB. Although approved for implementation at
regional (L4) hospital, only 1/34 (3%) reported possession of LPA platform, which they were
unfortunately unable to execute since they were trained by the test manufacturers. Lack of awareness
emerged as the 2nd main factor limiting the implementation of LPA. Surprisingly, almost 50% of health
administrators and practitioners were not aware of LPA as a diagnostic for TB. Without awareness, there
is no chance that such a diagnostic could be on the list of diagnostics to acquire by either HCF or district
health administration. Space intensiveness and laboriousness were highlighted as limitations for high
utilization by HCFs who had the LPA service. This is an eye opener for health technology developers to
make technologies that are compatible with the available infrastructure as well as investing in increasing
awareness and accessibility of these technologies especially in high TB burden settings.
Culture, the gold standard diagnostic for TB(31) was only found at a 5% implementation level across the
three countries. All culture laboratories were associated with level 5 HCFs (national, consultant or zonal
referral hospitals). On average culture laboratories serve 20 million or more people. Level 5 hospitals were
likely to perform culture and drug sensitivity testing (DST) than lower HCFs which did not have the
facilities. Presence of a culture laboratory at a facility did not change the time-to-culture-result, 2 months
at level 3, 4 and 5 HCFs. The limited availability of culture labs and very low referrals for culture shows
the three countries are not on course to achieve the universal DST access target of 100% by 2020 (WHO
framework of indicators and targets). While culture is relatively easy to perform and cheaper, practitioners
indicated they would spend a little more money for a hard to perform, expensive but accurate test with
shorter time-to-result diagnostic technology.
The low degree of coverage and utilization of molecular and culture tests revealed by our study is an
indication that TB is most likely under-diagnosed in the region and more so, drug resistant TB. Global
estimates show 3 million TB cases go undetected every year(7). Our ndings also indicate that universal
DST as recommended by WHO is currently unachievable until such a time when the countries have
developed required diagnostic capabilities(32). Treatment response monitoring needs of drug susceptible
TB in the region are largely met due to wide coverage of smear microscopy but not drug resistant TB
which requires a combination of microscopy and culture to monitor(33, 34). Challenges associated with
microscopy and culture for monitoring treatment response led the WHO to recognise the University of St
Andrews developed tuberculosis Molecular Bacterial Load Assay (TB-MBLA) as a candidate to replace
the two tests for monitoring TB treatment response(35, 36). Like other molecular diagnostics, maximising
uptake and utilization of TB-MBLA requires addressing the barriers highlighted in this paper.
Page 15/20
In the same trend, human resources capacity increased with the level of HCF, which partly explains higher
uptake and utilization of diagnostic services at these healthcare centres. Higher level HCFs are more likely
to be in the urban centres with many social amenities attractive to professionals to come work and stay.
Deliberate efforts must be made by national governments to ensure appointment and retention of
healthcare practitioners in rural areas.
Health budgets in the study countries are largely donor dependent and thus any economic downturns in
donor countries has ripple effect on the delivery of diagnostic and treatment services in LMIC settings.
This is more so in the era of the COVID-19 pandemic that has ravaged global economy with traditional
donor countries experiencing up to 10% or more shrinking of their economies(12). It is more prudent to
state that LMICs probably need to address the need to increase domestic funding for healthcare including
TB control services if the End TB Strategy has to be realised.
Engaging policymakers unravelled valuable ideas on how to practically increase research impact and
domestic nancing to sustain uptake of health technologies and ensure quality healthcare. A Health tax
on particular goods and services to build revenue base for funding healthcare programmes, research and
innovation was recommended as the best way to go. The views from policy makers clearly demonstrate
how an invaluable partner they are in research and its translation to policy and practice. Response to
COVID-19 is a good example where in most countries scientists and policy makers have worked hand-inhand to use available knowledge and tools to save lives whilst search for more effective medical
remedies goes on.
Conclusion
Our results have revealed that the health system set up favours maximal uptake and utilization both
molecular and microbiological diagnostics at tertiary rather than lower healthcare levels. They point to a
hub-centralised model of implementation model as the most effective for maximising uptake and
utilization of molecular diagnostics. It is important to note, however, that the success of a centralised
system also requires unlocking the health system barriers to increase awareness, smoothen sample
referral path and shorten results turn-around-time(37). Centralised system may mean low access to
diagnostic services by people in rural and hard to reach areas, thus innovating ways to ensure access by
such communities are crucial. The ndings also show low diagnostic capacity for drug resistant
tuberculosis in the region, which means they are far from achieving the universal DST recommended by
WHO. This paper further emphasises that health system bottlenecks are multifactorial and thus call for
multisectoral interdisciplinary approach to address them.
This paper follows the Squire style of reporting (see Additional le 3).
List Of Abbreviations
Page 16/20
TB: Tuberculosis, HCF: Healthcare facility, WHO: World Health Organization, LPA: Line Probe Assay, DST:
Drug Sensitivity Testing, MTB: Mycobacterium tuberculosis, RIF: Rifampicin.
Declarations
Ethics approval and consent to participate
The study gained ethical approval from respective institutional and national ethics committees
represented in the consortium. In the UK, approval was obtained from University Teaching and Research
Ethics Committee of University of St Andrews (MD12073), Uganda: Makerere University Institutional
Research Ethics Board (IRB) and National Council of Science and Technology (HS 2129), Kenya: KEMRI
Scienti c and Ethics Review Unit (KEMRI/RES/7/3/1) and Tanzania: KCRI and Mbeya and southern
highlands zonal IRBs and National Health Research Ethics Committee (NatHREC) at NIMR headquarters
(NIMR/HQ/R.8a/vol.IX/1317). In addition to ethics approvals, access permissions were sought and
obtained from local government authorities and healthcare facilities involved in the study.
Consent for publication
Not applicable.
Availability of data and materials
The quantitative data analyzed during the current study will not be made publicly available but are
available from the corresponding author on reasonable request. The qualitative (transcripts) data
analyzed during the current study are not publicly available due to them containing information that
could compromise research participant privacy; the data collection tools are available on request.
Competing interests
The authors declare no con ict of interest.
Funding
The study was funded by the European and Developing Countries Clinical Trials Partnership (EDCTP),
grant TWENDE-EDCTP-CSA-2014-283.
Authors' contributions
NEN, EA, MJ, SHG: Conceived and designed the study; WSFO, IM, AL, FN, KK, BM, EFM, ES, HM, DK, SM,
BTM: Developed the research tools and collected the data; FO, IM, FN, WO, LM, NEN, WS: led database
cleaning and data analysis; NEN & WS: drafted the manuscript; WS & AA: drew the gures and maps; All
authors: reviewed the manuscript and SHG: proof read the manuscript.
Acknowledgements
Page 17/20
The authors acknowledge the contributions of Dr Ewan Chirnside and Prof Gibson Kibiki in the initial
study conception, design and implementation of the study. Prof Kibiki also played a big role in linking the
TWENDE consortium to East African Health Research Commission (EAHRC). As a result of his effort,
EAHRC o cially adopted TWENDE as a research consortium for generating evidence needed for
translation of health technologies to policy and practice in the East African Community. Special thanks to
the healthcare administrators and practitioners, and policy makers who participated in the study.
References
1. World Health Organisation. WHO Coronavirus Disease (COVID-19) Dashboard [Internet]. WHO Health
Emergency Dashboard. 2020 [cited 2020 Jul 25]. p. 1–8. Available from: https://covid19.who.int
2. WHO. Statement from Dr Mario Raviglione, WHO Director, Stop TB Department. Who [Internet].
2012;11:26–8. Available from: https://www.who.int/tb/features_archive/mr_statement/en/
3. Nathavitharana RR, Friedland JS. A tale of two global emergencies: Tuberculosis control efforts can
learn from the Ebola outbreak. Eur Respir J [Internet]. 2015;46(2):293–6. Available from:
http://dx.doi.org/10.1183/13993003.00436-2015
4. World Health Organisation. Tuberculosis-Key facts. Geneva; 2020.
5. World Health Organization. Global Tuberculosis Report 2019 [Internet]. WHO Press. Geneva; 2019.
Available from: https://www.who.int/tb/publications/global_report/en/
6. Houben RMGJ, Dodd PJ. The Global Burden of Latent Tuberculosis Infection: A Re-estimation Using
Mathematical Modelling. PLoS Med. 2016;13(10):1–13.
7. Daniels B, Kwan A, Pai M, Das J. Lessons on the quality of tuberculosis diagnosis from standardized
patients in China, India, Kenya, and South Africa. Vol. 16, Journal of Clinical Tuberculosis and Other
Mycobacterial Diseases. 2019.
8. World Health Organisation. Molecular line probe assays for rapid screening of patients at risk of
multi-drug resistant tuberculosis. Geneva; 2008.
9. World Health Organisation. Automated Real-time Nucleic Acid Ampli cation Technology for Rapid
and Simultaneous Detection of Tuberculosis and Rifampicin Resistance : Xpert MTB / RIF System.
Geneva; 2011.
10. Albert H, Nathavitharana RR, Isaacs C, Pai M, Denkinger CM, Boehme CC. Development, roll-out and
impact of Xpert MTB/RIF for tuberculosis: What lessons have we learnt and how can we do better?
Eur Respir J [Internet]. 2016;48(2):516–25. Available from:
http://dx.doi.org/10.1183/13993003.00543-2016
11. World Health Organization Regional O ce for Europe. Rapid communication on the role of the
GeneXpert® platform for rapid molecular testing for SARS-CoV-2 in the WHO European Region. 2020;
(1 April 2020):1–8.
12. Hogan AB, Jewell BL, Sherrard-smith E, Vesga JF, Watson OJ, Whittaker C, et al. Potential impact of
the COVID-19 pandemic on HIV , tuberculosis , and malaria in low-income and middle-income
Page 18/20
countries : a modelling study. Lancet Glob Heal [Internet]. 2020;(20):1–10. Available from:
http://dx.doi.org/10.1016/S2214-109X(20)30288-6
13. World Health Organization. END TB Global Tuberculosis Report 2017. Geneva; 2017.
14. Sabiiti W, on behalf of the TWENDE Consortium. Beyond the Numbers: Interpreting WHO’s Global
Tuberculosis Report 2016 to Inform TB Policy and Practice in the East African Community [Internet].
Vol. 01, East African Health Research Journal. 2017. Available from: www.eahealth.org
15. World Health Organisation. End TB Strategy: global strategy and targets for tuberculosis prevention,
care and control after 2015. World Heal Origanisation. 2013;53(9):1689–99.
16. Hays JP, Mitsakakis K, Luz S, van Belkum A, Becker K, van den Bruel A, et al. The successful uptake
and sustainability of rapid infectious disease and antimicrobial resistance point-of-care testing
requires a complex ‘mix-and-match’ implementation package. Eur J Clin Microbiol Infect Dis.
2019;38(6):1015–22.
17. Masini E, Hanson C, Ogoro J, Brown J, Ngari F, Mingkwan P, et al. Using Patient-Pathway Analysis to
Inform a Differentiated Program Response to Tuberculosis: The Case of Kenya. J Infect Dis.
2017;216(June 2016):S714–23.
18. Hanson C, Osberg M, Brown J, Durham G, Chin DP. Finding the Missing Patients with Tuberculosis:
Lessons Learned from Patient-Pathway Analyses in 5 Countries. J Infect Dis.
2017;216(August):S686–95.
19. Study C. Patient Pathway Analysis for DSD of TB in Kenya.
20. APA news. Tanzania enters middle income country status. APA news. 2020 Jul 2;1–2.
21. World Health Organisation. Early TB detection [Internet]. Geneva; 2018. Available from:
https://www.who.int/tb/areas-of-work/laboratory/early-detection/en/
22. Desikan P. Sputum smear microscopy in tuberculosis: Is it still relevant? Tuberculosis. Indian J Med
Res. 2013;137(3):442–4.
23. Sabiiti W, Mtafya B, Kuchaka D, Azam K, Viegas S, Mdolo A, et al. Optimising molecular diagnostic
capacity for effective control of tuberculosis in high-burden settings. Int J Tuberc Lung Dis.
2016;20(8):1004–9.
24. Rieder HL, Van Deun A, Kam KM, Kim SJ, Chonde TM, Trébucq A, et al. Priorities for tuberculosis
bacteriology services in low-income countries. Second edition. Paris: International Union Against
Tuberculosis and Lung Disease, 2007. [Internet]. 2nd ed. Iuatld. Paris: International Union Against
Tuberculosis and Lung Disease (The Union); 2007. 1–118 p. Available from:
https://tbrieder.org/publications/books_english/red_book.pdf
25. Enos M, Sitienei J, Ong’ang’o J, Mungai B, Kamene M, Wambugu J, et al. Kenya tuberculosis
prevalence survey 2016: Challenges and opportunities of ending TB in Kenya. PLoS One.
2018;13(12):1–19.
26. Oliwa JN, Maina J, Ayieko P, Gathara D, Kathure IA, Masini E, et al. Variability in distribution and use
of tuberculosis diagnostic tests in Kenya: A cross-sectional survey. BMC Infect Dis. 2018;18(1).
Page 19/20
27. Pooran A, Theron G, Zijenah L, Chanda D, Clowes P, Mwenge L, et al. Point of care Xpert MTB/RIF
versus smear microscopy for tuberculosis diagnosis in southern African primary care clinics: a
multicentre economic evaluation. Lancet Glob Heal [Internet]. 2019;7(6):e798–807. Available from:
http://dx.doi.org/10.1016/S2214-109X(19)30164-0
28. Sohn H, Kasaie P, Kendall E, Gomez GB, Vassall A, Pai M, et al. Informing decision-making for
universal access to quality tuberculosis diagnosis in India: An economic-epidemiological model.
BMC Med. 2019;17(1):1–11.
29. Schumacher SG. Xpert ultra and MTB/RIF same price. 2017;(June). Available from:
https://www.teachepi.org/wp-content/uploads/Courses/ADV-2017/Xpert-MTB-RIF-Ultra-GeneXpertOMNI-status-update_18JUN2017.pdf
30. Ejalu DL. Cost-effectiveness analysis of genexpert omni compared to genexpert mtb/rif for point of
care diagnosis of tuberculosis among presumptive cases in pingire health centre iii, serere district.
Vol. 10, MSPH. Makerere University; 2018.
31. Sabiiti W, Mtafya B, Kuchaka D, Azam K, Viegas S, Mdolo A, et al. Optimising molecular diagnostic
capacity for effective control of tuberculosis in high-burden settings. Int J Tuberc Lung Dis.
2016;20(8).
32. de Vries SG, Cremers AL, Heuvelings CC, Greve PF, Visser BJ, Bélard S, et al. Barriers and facilitators
to the uptake of tuberculosis diagnostic and treatment services by hard-to-reach populations in
countries of low and medium tuberculosis incidence: a systematic review of qualitative literature.
Lancet Infect Dis. 2017;17(5):e128–43.
33. World Health Organisation. Treatment of tuberculosis guidelines. 4th ed. Menzies R, Steingart K,
Nunn A, Philips P, Schunemann H, McLellan F, et al., editors. Vol. WHO/HTM/TB, World Health
Organisation. Geneva: World Health Organisation; 2010. 1–147 p.
34. World Health Organization (WHO). Companion handbook to the WHO guidelines for the
programmatic management of drug-resistant tuberculosis. World Health Organization. Geneva; 2014.
464 p.
35. World Health Organization. Global tuberculosis report 2018 [Internet]. Geneva; 2018. Available from:
http://apps.who.int/iris/bitstream/handle/10665/274453/9789241565646-eng.pdf?ua=1
36. Sabiiti W, Azam K, Farmer ECW, Kuchaka D, Mtafya B, Bowness R, et al. Tuberculosis bacillary load,
an early marker of disease severity: The utility of tuberculosis Molecular Bacterial Load Assay.
Thorax. 2020;1–3.
37. Nalugwa T, Shete PB, Nantale M, Farr K, Ojok C, Ochom E, et al. Challenges with scale-up of
GeneXpert MTB/RIF® in Uganda: A health systems perspective. BMC Health Serv Res. 2020;20(1):1–
7.
Page 20/20